Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205.
Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104.
Proc Natl Acad Sci U S A. 2020 Dec 15;117(50):32066-32077. doi: 10.1073/pnas.2020617117. Epub 2020 Nov 25.
In untreated HIV-1 infection, rapid viral evolution allows escape from immune responses. Viral replication can be blocked by antiretroviral therapy. However, HIV-1 persists in a latent reservoir in resting CD4 T cells, and rebound viremia occurs following treatment interruption. The reservoir, which is maintained in part by clonal expansion, can be measured using quantitative viral outgrowth assays (QVOAs) in which latency is reversed with T cell activation to allow viral outgrowth. Recent studies have shown that viruses detected in QVOAs prior to treatment interruption often differ from rebound viruses. We hypothesized that autologous neutralizing antibodies directed at the HIV-1 envelope (Env) protein might block outgrowth of some reservoir viruses. We modified the QVOA to reflect pressure from low concentrations of autologous antibodies and showed that outgrowth of a substantial but variable fraction of reservoir viruses is blocked by autologous contemporaneous immunoglobulin G (IgG). A reduction in outgrowth of >80% was seen in 6 of 15 individuals. This effect was due to direct neutralization. We established a phylogenetic relationship between rebound viruses and viruses growing out in vitro in the presence of autologous antibodies. Some large infected cell clones detected by QVOA carried neutralization-sensitive viruses, providing a cogent explanation for differences between rebound virus and viruses detected in standard QVOAs. Measurement of the frequency of reservoir viruses capable of outgrowth in the presence of autologous IgG might allow more accurate prediction of time to viral rebound. Ultimately, therapeutic immunization targeting the subset of variants resistant to autologous IgG might contribute to a functional cure.
在未经治疗的 HIV-1 感染中,病毒的快速进化使其能够逃避免疫反应。抗逆转录病毒疗法可以阻断病毒复制。然而,HIV-1 会在静止的 CD4 T 细胞中潜伏储存,并且在治疗中断后会出现病毒反弹。该储存库部分是通过克隆扩增维持的,可以使用定量病毒扩增检测(QVOA)来测量,该检测通过 T 细胞激活逆转潜伏期以允许病毒扩增。最近的研究表明,在治疗中断前通过 QVOA 检测到的病毒通常与反弹病毒不同。我们假设针对 HIV-1 包膜(Env)蛋白的自体中和抗体可能会阻止部分储存病毒的生长。我们修改了 QVOA 以反映来自低浓度自体抗体的压力,并表明自体同时免疫球蛋白 G(IgG)可以阻止大量但可变部分储存病毒的生长。在 15 个人中有 6 个人看到了超过 80%的生长减少。这种效果是由于直接中和。我们建立了反弹病毒和在存在自体抗体的情况下在体外生长的病毒之间的系统发育关系。通过 QVOA 检测到的一些大的感染细胞克隆携带对中和敏感的病毒,为反弹病毒和在标准 QVOA 中检测到的病毒之间的差异提供了一个有说服力的解释。测量在自体 IgG 存在下能够生长的储存病毒的频率可能会更准确地预测病毒反弹的时间。最终,针对对自体 IgG 具有抗性的变体的治疗性免疫接种可能有助于功能性治愈。